StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $18.35 | $15.67 | -14.60% | 0.5M |
| 05-12 | $15.60 | $15.80 | +1.28% | 0.3M |
| 05-13 | $14.83 | $15.81 | +6.61% | 0.4M |
| 05-14 | $16.04 | $15.79 | -1.56% | 0.1M |
| 05-15 | $15.49 | $15.36 | -0.84% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $22.07M | $99.99M | $73.40M | $46.04M |
Operating Income | $-5.57M | $-16.34M | $-14.57M | $-11.97M |
Net Income | $-6.69M | $-21.46M | $-18.74M | $-8.65M |
EPS (Diluted) | $-0.20 | $-0.66 | $-0.58 | $-0.47 |
Total Assets | $98.90M | $105.56M | $107.25M | $106.11M |
Total Liabilities | $84.44M | $86.53M | $88.74M | $86.68M |
Cash & Equivalents | $14.78M | $21.69M | $20.65M | $22.86M |
Free Cash Flow OCF − CapEx | $-6.02M | $-11.34M | $-11.75M | $-9.77M |
Shares Outstanding | 33.91M | 33.57M | 33.28M | 33.04M |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.